A Momentous Recognition at the "Oscars of Science" (Image Credits: Unsplash)
Philadelphia — A team of researchers celebrated a landmark achievement with the $3 million Breakthrough Prize in Life Sciences, often called the "Oscars of science." Jean Bennett, Albert Maguire, and Katherine High earned the honor for developing Luxturna, the first FDA-approved gene therapy for an inherited form of blindness.[1][2] Their 25-year effort has not only restored vision for patients but also sparked a wave of innovation in retinal treatments affecting millions worldwide.
A Momentous Recognition at the "Oscars of Science"
The glitzy ceremony in Los Angeles on April 18 marked the culmination of decades of work. Founders including Sergey Brin, Priscilla Chan, Mark Zuckerberg, Yuri and Julia Milner, and Anne Wojcicki established the prizes in 2012 to celebrate transformative research.[1] Bennett and Maguire, a married couple and emeritus professors at the University of Pennsylvania’s Perelman School of Medicine, shared the award with High, founding director of CHOP’s Raymond G. Perelman Center for Cellular and Molecular Therapeutics.
University leaders hailed the trio’s resilience. "Even 20 years ago, treating people with gene therapy was seen by some as an impossibility," said Jonathan Epstein, dean of the Perelman School of Medicine.[1] Their persistence delivered results that provide sight to individuals who might otherwise lose it in early childhood. Penn now ties Harvard with nine Breakthrough laureates.
Origins in Blind Dogs and Bold Visions
Bennett and Maguire met at Harvard Medical School in the 1980s, paired to dissect a brain. They joined Penn’s Scheie Eye Institute in the 1990s, drawn to gene therapy for Leber congenital amaurosis (LCA), a rare disorder from RPE65 gene mutations that robs vision from birth and leads to total blindness by the teens or 20s.[3]
Early tests targeted blind dogs at Penn’s veterinary school with a similar condition. Using a virus to deliver a functional RPE65 gene, they injected one eye per animal. A technician soon called with excitement: "They can see!" The dogs navigated obstacle courses effortlessly post-treatment. Bennett and Maguire even adopted two — Venus and Mercury — as pets.[1]
- 1980s: Couple envisions gene therapy amid skepticism.
- 1990s: Lab work on mice and dogs proves concept.
- 2004: High establishes CHOP center for vector production.
- 2007: First human injection at CHOP.
The Mechanism That Delivers Vision
Luxturna employs an adeno-associated virus (AAV) as a carrier to insert a working RPE65 gene into retinal cells. This corrects faulty proteins, enabling light-sensitive cells to function again. Spark Therapeutics, a CHOP spinout, manufactured the therapy for FDA approval in 2017 — the first for any inherited disease.[1]
A pivotal Lancet study confirmed efficacy: treated patients showed major gains in multi-luminance mobility testing over controls. In initial trials, 72 percent of 37 participants achieved maximum low-light improvement, with many gaining peripheral and central vision.[2] Hundreds have received it globally since.
Profound Changes in Patients’ Lives
One patient discerned her child’s face, wood grain, and wind-swept branches for the first time. Another spotted a star six days post-procedure or navigated Philadelphia streets at night unaided.[3] These stories underscore the therapy’s real-world impact.
"The nice thing about being young and naive is I didn’t know what I didn’t know," Bennett reflected. Maguire likened early ambitions to "wanting to go to the moon in 1950." High’s hemophilia work complemented theirs, advancing vector tech despite setbacks.[2]
Business Momentum in Gene Therapy
The success fueled a sector boom. Their trailblazing supports over 140 retinal trials for conditions like macular degeneration and diabetic retinopathy, impacting 30 million Americans; 80 more are active.[1] CHOP CEO Madeline Bell noted decades of investment yielded innovations giving hope worldwide.
Spark’s commercialization set precedents, including a 2024 FDA nod for High’s hemophilia therapy. Penn President J. Larry Jameson praised such rigor for expanding medicine’s frontiers.
This prize validates long-term bets on biotech. As gene therapies proliferate, their model — academic collaboration, spinouts, regulatory wins — shapes a multi-billion-dollar industry.
Key Takeaways
- Luxturna marked the first FDA-approved gene therapy for inherited disease in 2017.
- Over 140 follow-on trials target vision loss for millions.
- 25 years of work by Penn and CHOP teams earned a $3 million prize.
The story of Luxturna shows science’s power when persistence meets innovation. Patients now see stars and faces long denied them, while the field races toward broader cures. What do you think about this milestone in gene therapy? Tell us in the comments.
